Sanofi/UCB partner in immunology
This article was originally published in Scrip
Executive Summary
Sanofi and UCB have entered into a collaboration to discover and develop new anti-inflammatory medicines for immune-mediated diseases. The partners will share costs and profits equally, but UCB will stand to receive more than €100m from Sanofi in up-front and milestone payments.